Weekly Investment Analysts’ Ratings Updates for Nuvation Bio (NUVB)

Nuvation Bio (NYSE: NUVB) has recently received a number of price target changes and ratings updates:

• 3/12/2025 – Nuvation Bio is now covered by analysts at Jones Trading. They set a “buy” rating and a $10.00 price target on the stock.
• 3/11/2025 – Nuvation Bio was upgraded by analysts at Jones Trading to a “strong-buy” rating.
• 3/10/2025 – Nuvation Bio had its price target lowered by analysts at HC Wainwright from $11.00 to $10.00. They now have a “buy” rating on the stock.
• 3/3/2025 – Nuvation Bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
• 1/23/2025 – Nuvation Bio had its price target raised by analysts at HC Wainwright from $10.00 to $11.00. They now have a “buy” rating on the stock.

Nuvation Bio Price Performance

NYSE:NUVB traded up $0.07 during mid-day trading on Monday, reaching $1.96. The stock had a trading volume of 3,704,017 shares, compared to its average volume of 1,981,167. The stock has a 50-day simple moving average of $2.26 and a two-hundred day simple moving average of $2.51. Nuvation Bio Inc. has a 12 month low of $1.67 and a 12 month high of $4.16. The stock has a market capitalization of $662.12 million, a PE ratio of -0.90 and a beta of 1.47.

Hedge Funds Weigh In On Nuvation Bio

A number of institutional investors have recently modified their holdings of the business. FMR LLC grew its position in Nuvation Bio by 54.9% in the fourth quarter. FMR LLC now owns 45,285,572 shares of the company’s stock valued at $120,460,000 after acquiring an additional 16,046,701 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Nuvation Bio by 45.4% during the 4th quarter. Vanguard Group Inc. now owns 15,732,567 shares of the company’s stock valued at $41,849,000 after purchasing an additional 4,913,820 shares during the last quarter. Geode Capital Management LLC increased its position in Nuvation Bio by 22.9% during the 4th quarter. Geode Capital Management LLC now owns 4,951,195 shares of the company’s stock worth $13,174,000 after purchasing an additional 922,503 shares in the last quarter. State Street Corp lifted its stake in Nuvation Bio by 4.8% in the 3rd quarter. State Street Corp now owns 4,166,441 shares of the company’s stock valued at $9,541,000 after purchasing an additional 191,031 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new stake in Nuvation Bio in the fourth quarter valued at approximately $11,077,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.